Agent for improvement of insulin resistance

A novel dosage regimen of GLP-1 receptor agonists causes little or no side effects or drug interactions and is suitable for improving insulin resistance. Also provided is an insulin resistance improver for use in the dosage regimen. The dosage regimen comprises repeatedly administering, preferably i...

Full description

Saved in:
Bibliographic Details
Main Authors YUTAKA MASUDA, NAOMI WAKABAYASHI, YURIKO HARADA
Format Patent
LanguageEnglish
Published 30.11.2006
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

Abstract A novel dosage regimen of GLP-1 receptor agonists causes little or no side effects or drug interactions and is suitable for improving insulin resistance. Also provided is an insulin resistance improver for use in the dosage regimen. The dosage regimen comprises repeatedly administering, preferably in a non-invasive manner, a GLP-1 receptor agonist at least before eating for a predetermined period of time to create a condition similar to what is observed with postprandial temporary secretion of the endogenous GLP-1 receptor agonist, rather than administering it continuously. This creates a similar or enhanced variation in the plasma levels of GLP-1 receptor agonist as compared to the circadian variation of the endogenous GLP-1 receptor agonist in a healthy individual. A pharmaceutical composition for use in the dosage regimen containing GLP-1 receptor agonist as an active ingredient is also provided.
AbstractList A novel dosage regimen of GLP-1 receptor agonists causes little or no side effects or drug interactions and is suitable for improving insulin resistance. Also provided is an insulin resistance improver for use in the dosage regimen. The dosage regimen comprises repeatedly administering, preferably in a non-invasive manner, a GLP-1 receptor agonist at least before eating for a predetermined period of time to create a condition similar to what is observed with postprandial temporary secretion of the endogenous GLP-1 receptor agonist, rather than administering it continuously. This creates a similar or enhanced variation in the plasma levels of GLP-1 receptor agonist as compared to the circadian variation of the endogenous GLP-1 receptor agonist in a healthy individual. A pharmaceutical composition for use in the dosage regimen containing GLP-1 receptor agonist as an active ingredient is also provided.
Author YURIKO HARADA
YUTAKA MASUDA
NAOMI WAKABAYASHI
Author_xml – fullname: YUTAKA MASUDA
– fullname: NAOMI WAKABAYASHI
– fullname: YURIKO HARADA
BookMark eNrjYmDJy89L5WTQdkxPzStRSMsvUsjMLSjKL0vNBfHz0xQy84pLczLzFIpSizOLSxLzklN5GFjTEnOKU3mhNDeDsptriLOHbmpBfnxqcUFicmpeakm8Y6iRgYGZkamBsYm5o6ExcaoADz4sLg
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID AU2006250347A1
GroupedDBID EVB
ID FETCH-epo_espacenet_AU2006250347A13
IEDL.DBID EVB
IngestDate Fri Jul 19 14:52:51 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_AU2006250347A13
Notes Application Number: AU20060250347
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20061130&DB=EPODOC&CC=AU&NR=2006250347A1
ParticipantIDs epo_espacenet_AU2006250347A1
PublicationCentury 2000
PublicationDate 20061130
PublicationDateYYYYMMDD 2006-11-30
PublicationDate_xml – month: 11
  year: 2006
  text: 20061130
  day: 30
PublicationDecade 2000
PublicationYear 2006
RelatedCompanies ASUBIO PHARMA CO., LTD
RelatedCompanies_xml – name: ASUBIO PHARMA CO., LTD
Score 2.65947
Snippet A novel dosage regimen of GLP-1 receptor agonists causes little or no side effects or drug interactions and is suitable for improving insulin resistance. Also...
SourceID epo
SourceType Open Access Repository
SubjectTerms HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title Agent for improvement of insulin resistance
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20061130&DB=EPODOC&locale=&CC=AU&NR=2006250347A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQSTEyTUkGNkV1k4F1ja5JormRbmKqpbluUpJBIuiOSoNU8KYwXz8zj1ATrwjTCCaGHNheGPA5oeXgwxGBOSoZmN9LwOV1AWIQywW8trJYPykTKJRv7xZi66IG7x0bAstkNRcnW9cAfxd_ZzVnZ2BPUs0vCCwHrO2NTcwdgX0lVmBD2hyUH1zDnED7UgqQKxU3QQa2AKB5eSVCDEypecIMnM6wu9eEGTh8oVPeQCY09xWLMGg7gvZBKQCbmQqZ4LEA8NCeQn6aAnRFuQKw7wxqDwKVizIou7mGOHvoAm2Nh3sy3jEU2YnGYgwswO5_qgSDQpJRWqpFolFySkpimkmqZSLoIFlgGyLZJNkgNdUi1VSSQQafSVL4paUZuMCDCuDDDGUYWEqKSlNlgdVsSZIcOHQAUJaAcA
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQSTEyTUkGNkV1k4F1ja5JormRbmKqpbluUpJBIuiOSoNU8KYwXz8zj1ATrwjTCCaGHNheGPA5oeXgwxGBOSoZmN9LwOV1AWIQywW8trJYPykTKJRv7xZi66IG7x0bAstkNRcnW9cAfxd_ZzVnZ2BPUs0vCCwHrO2NTcwdgX0lVmAj2xyUH1zDnED7UgqQKxU3QQa2AKB5eSVCDEypecIMnM6wu9eEGTh8oVPeQCY09xWLMGg7gvZBKQCbmQqZ4LEA8NCeQn6aAnRFuQKw7wxqDwKVizIou7mGOHvoAm2Nh3sy3jEU2YnGYgwswO5_qgSDQpJRWqpFolFySkpimkmqZSLoIFlgGyLZJNkgNdUi1VSSQQafSVL4peUZOD1CfH3ifTz9vKUZuMADDOCDDWUYWEqKSlNlgVVuSZIcOKQAgfCDYw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Agent+for+improvement+of+insulin+resistance&rft.inventor=YUTAKA+MASUDA&rft.inventor=NAOMI+WAKABAYASHI&rft.inventor=YURIKO+HARADA&rft.date=2006-11-30&rft.externalDBID=A1&rft.externalDocID=AU2006250347A1